OVERVIEW

Are We Ready for Psychedelics? is organized by CME Outfitters, LLC.

Premiere Date: Friday, May 8, 2020
Credit Expiration Date: Saturday, May 8, 2021

This activity offers CE credit for:
• Physicians (CME)
• Pharmacists (ACPE)
• Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Information:
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to PAs: PAs may claim a maximum of .25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

CPE Credit (Pharmacists):
ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .25 contact hours (0.025 CEUs)

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Statement of Need:
A variety of psychedelic agents have been studied for the clinical purpose of treating psychiatric disorders, such as psilocybin for mood and anxiety disorders and 3,4-methylenedioxy-methamphetamine (MDMA) for PTSD. While they were effective in reducing symptoms, with many participants rating their experiences as among the most profound and meaningful of their lives, neuroimaging studies with these and other psychedelic agents are still in their early stages. Given the strength of these findings, more extensive studies are called for, as are studies in more diverse populations, with additional thought given as to how to deal with the unique legal, ethical, and regulatory issues surrounding the clinical use of these agents.

In this CMEOCast podcast, expert faculty discuss the complex history and focus on the preliminary clinical data that support the use of psychedelics for the management of treatment resistant conditions.

Learning Objectives:
At the end of this CE activity, participants should be able to:
• Evaluate the role of psychedelic agents for the management of mood and anxiety disorders